Richard Colvin, MD, PhD, has served as chief medical officer of bluebird since March 2021. Rich joined bluebird in 2018 and was medical lead of the thalassemia program and led clinical research and development prior to becoming CMO. Since Rich has been CMO, bluebird submitted and gained FDA approval for the gene therapies beti-cel for patients with beta-thalassemia and eli-cel for the treatment of patients with cerebral adrenoleukodystrophy and bluebird has completed its submission of the BLA for lovo-cel, a gene therapy for the treatment of patients with sickle cell disease. Prior to bluebird, Rich was an executive director in translational medicine at Novartis where he led early-stage anti-infective and gene therapy development programs. Rich clinically trained in Internal Medicine and Infectious Diseases at the Brigham and Women’s Hospital and remains on faculty at Harvard Medical School. He sees patients in the Infectious Diseases clinic at Massachusetts General Hospital. Rich received his MD and PhD from Duke University School of Medicine.